Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
AssigneeNovabiotics Limited
InventorsDeborah O'NEIL, Vanessa DUNCAN
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising cysteamine or a derivative thereof for use in treating infections caused by yeasts or moulds.
Claims9
A composition comprising cysteamine or a derivative thereof for use in the treatment or prevention of an infection caused by yeasts and/or moulds.
A composition comprising cysteamine for use in the prevention or treatment of any one or more of the group consisting of:
- candidiasis (including OPC), aspergillosis (including bronchopulmonary aspergillosis, chronic pulmonary aspergillosis and aspergillomata), cystic fibrosis, athlete's foot;
- basidiodiabolomycosis;
- blastomycosis;
- coccidioidomycosis cryptoccocis;
- COPD;
- basal meningitis;
- dermatophytosis;
- onchomycosis;
- dermatophytids;
- endothrix;
- exothrix;
- fungal meningitis, fungemia, heaves;
- histoplasmosis, mycosis, myrinogmycosis, paracoccidioidomycosis, penicilliosis, piedra, pneumocytosis pneumonia, sporptrichosis, tinea, zeospora and zygomycosis.
A method of treating or preventing an infection caused by yeasts or moulds in a subject comprising administering a pharmaceutically effective amount of a composition comprising cysteamine or a derivative thereof.
Dependencies are inferred from the claim text.